Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
Megan R W BarberJohn G HanlyLi SuMurray B UrowitzYvan St PierreJuanita Romero-DiazCaroline GordonSang-Cheol BaeSasha BernatskyDaniel J WallaceJoan T MerrillDavid Alan IsenbergAnisur RahmanEllen M GinzlerMichelle A PetriIan N BruceMary A DooleyPaul R FortinDafna D GladmanJorge Sanchez-GuerreroKristjan SteinssonRosalind Ramsey-GoldmanMunther A KhamashtaCynthia AranowMeggan MackayGraciela S AlarcónSusan ManziOla NivedAndreas JönsenAsad A ZomaRonald F Van VollenhovenManuel Ramos-CasalsGuillermo Ruiz-IrastorzaS Sam LimKenneth C KalunianMurat InancDiane L KamenChristine A PeschkenSøren JacobsenAnca AskanaseVernon FarewellThomas StollJill BuyonAnn Elaine ClarkePublished in: Arthritis care & research (2020)
Patients with the highest SDI scores incur 10-year cumulative costs that are ~9-fold higher than those with the lowest SDI scores. By estimating the damage trajectory and incorporating annual costs, data on damage can be used to estimate future costs, which is critical knowledge for evaluating the cost-effectiveness of novel therapies.